STOCK TITAN

Hansa Biopharma AB - HNSBF STOCK NEWS

Welcome to our dedicated news page for Hansa Biopharma AB (Ticker: HNSBF), a resource for investors and traders seeking the latest updates and insights on Hansa Biopharma AB.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Hansa Biopharma AB's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Hansa Biopharma AB's position in the market.

Rhea-AI Summary
Hansa Biopharma (Nasdaq Stockholm: HNSA) announced that imlifidase significantly reduced donor-specific antibodies (DSAs) by 94.4% within 5 days of treatment, compared to 35.6% reduction with standard of care, in the 16-HMedIdeS-12 phase 2 trial for patients with antibody mediated rejection (AMR) episodes following a kidney transplant. The trial also showed a 74% six-month graft survival and eGFR of 30mL/min/1.73m2 in the imlifidase arm, with a safety profile consistent with previous clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Hansa Biopharma AB

OTC:HNSBF

HNSBF Rankings

HNSBF Stock Data

154.33M
37.69M
13.64%
31.51%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Sweden
Lund